Legend Biotech Corp (LEGN)
46.06
+2.24
(+5.11%)
USD |
NASDAQ |
Mar 24, 16:00
45.14
-0.92
(-2.00%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 7.711B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 18.56% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 71.40 |
| Price to Book Value | 13.70 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.3363 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
MT Newswires
01/30 10:01
Yahoo
01/27 09:54
MT Newswires
01/27 09:24
MT Newswires
01/25 07:45
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 06/01/2023* | -- | Results | Q1 2023 | -- | -- | -- | |
| 08/05/2022 | -- | Results | Q2 2022 | -0.41 | -0.36 | -13.83% | |
| 06/01/2022 | -- | Results | Q1 2022 | -0.25 | -0.42 | 41.66% | |
| 03/18/2022 | -- | Results | Q4 2021 | -0.30 | -0.19 | -54.64% | |
| 11/16/2021 | -- | Results | Q3 2021 | -0.43 | -0.46 | 5.84% | |
| 08/23/2021 | -- | Results | Q2 2021 | -0.33 | -0.38 | 12.00% | |
| 05/18/2021 | -- | Results | Q1 2021 | -0.30 | -0.39 | 23.08% | |
| 03/18/2021 | -- | Results | Q4 2020 | -0.22 | -0.30 | 26.67% |
*Estimated Date/Time
Earnings
Profile
Edit
| Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy is for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from North America. |
| URL | https://www.legendbiotech.com |
| Investor Relations URL | https://investors.legendbiotech.com/ |
| HQ State/Province | New Jersey |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | Jun. 01, 2023 (est.) |
| Last Earnings Release | Aug. 05, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 24, 2023.
Fundamentals
| Revenue (TTM) | 96.92M |
| Total Expenses (TTM) | 506.48M |
| Net Income (TTM) | -456.62M |
| Total Assets (Quarterly) | 1.023B |
| Total Liabilities (Quarterly) | 460.11M |
| Shareholders Equity (Quarterly) | 562.63M |
Ratings
Profile
Edit
| Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy is for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from North America. |
| URL | https://www.legendbiotech.com |
| Investor Relations URL | https://investors.legendbiotech.com/ |
| HQ State/Province | New Jersey |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | Jun. 01, 2023 (est.) |
| Last Earnings Release | Aug. 05, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| LEGN Tweets |